Camargos Sarah Teixeira, Cardoso Francisco, Momeni Parastoo, Gianetti Juliana Gurgel, Lees Andrew, Hardy John, Singleton Andrew
Universidade Federal de Minas Gerais, Department of Clinical and Neurological Sciences, Movement Disorders Group, Brazil.
Mov Disord. 2008 Jan 30;23(2):299-302. doi: 10.1002/mds.21842.
Dopa responsive Dystonia (DRD) was first described in 1971 and typically begins at childhood with gait dysfunction caused by foot dystonia progressing to affect other extremities. There is marked diurnal fluctuation and sustained improvement of symptoms with low dose levodopa therapy. Heterozygous mutation of the gene GCH1 has been shown to cause DRD. We studied GCH1 in nine patients with DRD from six families of Federal University of Minas Gerais Movement Disorders Clinic. We identified three mutations; two affected siblings carried a novel T209P mutation and two siblings from another family were compound heterozygous carriers of Met211Val and Lys224Arg mutations. To our knowledge this is the first report of GCH1 mutations underlying DRD in patients from Brazil.
多巴反应性肌张力障碍(DRD)于1971年首次被描述,通常始于儿童期,最初表现为足部肌张力障碍导致的步态功能障碍,随后进展至影响其他肢体。症状具有明显的日间波动,低剂量左旋多巴治疗可使症状持续改善。已证实基因GCH1的杂合突变可导致DRD。我们对米纳斯吉拉斯联邦大学运动障碍诊所六个家庭的九名DRD患者的GCH1基因进行了研究。我们鉴定出三个突变;两名患病兄弟姐妹携带一种新的T209P突变,另一个家庭的两名兄弟姐妹是Met211Val和Lys224Arg突变的复合杂合携带者。据我们所知,这是巴西患者中DRD潜在GCH1突变的首次报告。